ROIV - Conference and earnings call announcements

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) --  Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous in

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous injec

Namilumab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine believed to play a key role in the pathogenesis of sarcoidosis RESOLVE-Lung is a randomized, double-blind, placebo-controlled Phase 2 study designed to be supportive of registration that enrolled 107 pulmonary sarcoidosis patients whose disease is not well-controlled despite currently available treatments Topline results are expected by the end of calendar year 2024 Roivant (NASDAQ:ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announ

Three healthcare investor conferences in September across Boston, New York and LondonRoivant Investor Day will take place virtually on September 28th starting at 11 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) will participate in three healthcare investor conferences and hold an investor day in September: Citi BioPharma Conference in Boston on Wednesday, September 7thH.C. Wainwright Global Investment Conference in New York City on Monday, September 12th. Roivant's CEO Matt Gline will present at 8:30 a.m. EDT (webcast available at https://investor.roivant.com/news-events/events)Bank of America Global H

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) will participate in four upcoming healthcare investor conferences: UBS Global Healthcare Conference in New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline will present.H.C. Wainwright Global Investment Conference in Miami on Tuesday, May 24 at 8:30 a.m. EDT. CFO Richard Pulik will participate in a fireside chat.Jefferies Healthcare Conference in New York City on Wednesday, June 8 at 2:00 p.m. EDT. CEO Matt Gline will participate in a fireside chat.Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14 at 8:40 a.m. PDT / 11:4

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced that its CEO Matt Gline will present at Guggenheim's Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET. A live webcast will be available under "Events & Presentations" on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. About Roivant Sciences Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leve

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ETSVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET A live webcast of each presentation will be available under "Events & Presentations" on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events and an archived recording of the presentations will be available for 30 days. About Roivant SciencesRoivant's mission is to imp